Exact Mass: 407.1643

Exact Mass Matches: 407.1643

Found 68 metabolites which its exact mass value is equals to given mass value 407.1643, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Trifluoperazine

10-[3-(4-METHYL-piperazin-1-yl)-propyl]-2-trifluoromethyl-10H-phenothiazine

C21H24F3N3S (407.1643)


Trifluoperazine is only found in individuals that have used or taken this drug. It is a phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. [PubChem]Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent > C740 - Phenothiazine D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics KEIO_ID T122; [MS2] KO009263 KEIO_ID T122

   

Coelenterazine h

Renilla luciferin

C26H21N3O2 (407.1634)


   

Anlotinib

Anlotinib

C23H22FN3O3 (407.1645)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor

   

Anlotinib

1-[({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl}oxy)methyl]cyclopropan-1-amine

C23H22FN3O3 (407.1645)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor

   

Dansyl-L-arginine

5-[(diaminomethylidene)amino]-2-[5-(dimethylamino)naphthalene-1-sulfonamido]pentanoic acid

C18H25N5O4S (407.1627)


   

N-(7-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)acetamide

N-(7-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)acetamide

C20H25NO8 (407.158)


   

O-Methyl-waltherione A

O-Methyl-waltherione A

C24H25NO5 (407.1733)


   

4-(2-Hydroxy-3-methyl-3-butenyl)yukocitrine

4-(2-Hydroxy-3-methyl-3-butenyl)yukocitrine

C24H25NO5 (407.1733)


   

Tyloindicine J

Tyloindicine J

C24H25NO5 (407.1733)


   
   
   
   
   
   
   

trifluoperazine

Trifluoperazine aka 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine

C21H24F3N3S (407.1643)


N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent > C740 - Phenothiazine D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics

   
   

Asn Ser Ser Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-hydroxypropanamido]-3-hydroxybutanoic acid

C14H25N5O9 (407.1652)


   

Asn Ser Thr Ser

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-hydroxybutanamido]-3-hydroxypropanoic acid

C14H25N5O9 (407.1652)


   

Asn Thr Ser Ser

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]-3-hydroxypropanoic acid

C14H25N5O9 (407.1652)


   

Gln Ser Ser Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-hydroxypropanamido]-3-hydroxypropanamido]-3-hydroxypropanoic acid

C14H25N5O9 (407.1652)


   

Ser Asn Ser Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-hydroxybutanoic acid

C14H25N5O9 (407.1652)


   

Ser Asn Thr Ser

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-hydroxybutanamido]-3-hydroxypropanoic acid

C14H25N5O9 (407.1652)


   
   

Ser Gln Ser Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-carbamoylbutanamido]-3-hydroxypropanamido]-3-hydroxypropanoic acid

C14H25N5O9 (407.1652)


   

Ser Ser Asn Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-hydroxybutanoic acid

C14H25N5O9 (407.1652)


   

Ser Ser Gln Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxypropanamido]-4-carbamoylbutanamido]-3-hydroxypropanoic acid

C14H25N5O9 (407.1652)


   

Ser Ser Ser Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxypropanamido]-3-hydroxypropanamido]-4-carbamoylbutanoic acid

C14H25N5O9 (407.1652)


   

Ser Ser Thr Asn

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxypropanamido]-3-hydroxybutanamido]-3-carbamoylpropanoic acid

C14H25N5O9 (407.1652)


   

Ser Thr Asn Ser

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxybutanamido]-3-carbamoylpropanamido]-3-hydroxypropanoic acid

C14H25N5O9 (407.1652)


   
   

Ser Thr Ser Asn

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]-3-carbamoylpropanoic acid

C14H25N5O9 (407.1652)


   

Thr Asn Ser Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-hydroxypropanoic acid

C14H25N5O9 (407.1652)


   

Thr Ser Asn Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-hydroxypropanoic acid

C14H25N5O9 (407.1652)


   

Thr Ser Ser Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxypropanamido]-3-hydroxypropanamido]-3-carbamoylpropanoic acid

C14H25N5O9 (407.1652)


   

tributyl(1H-indol-6-yl)stannane

tributyl(1H-indol-6-yl)stannane

C20H33NSn (407.1635)


   
   

5,7-Dihydro-7,7-diphenyl-indeno[2,1-b]carbazole

5,7-Dihydro-7,7-diphenyl-indeno[2,1-b]carbazole

C31H21N (407.1674)


   

1H-Indole, 5-(tributylstannyl)-

1H-Indole, 5-(tributylstannyl)-

C20H33NSn (407.1635)


   

Ciforadenant

Ciforadenant

C20H21N7O3 (407.1706)


C308 - Immunotherapeutic Agent > C2139 - Immunostimulant Ciforadenant (CPI-444) is a potent, orally active and selective adenosine A2A receptor (A2AR) antagonist, which induces antitumor responses[1].

   

N2-[[5-(dimethylamino)-1-naphthyl]sulphonyl]-L-arginine

N2-[[5-(dimethylamino)-1-naphthyl]sulphonyl]-L-arginine

C18H25N5O4S (407.1627)


   

N-[7-(3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl)oxy-8-methyl-2-oxochromen-3-yl]acetamide

N-[7-(3,4-dihydroxy-5-methoxy-6,6-dimethyloxan-2-yl)oxy-8-methyl-2-oxochromen-3-yl]acetamide

C20H25NO8 (407.158)


   

S-(1-hydroxyhex-3-yl)-glutathion

S-(1-hydroxyhex-3-yl)-glutathion

C16H29N3O7S (407.1726)


   

2-[(Z)-(2-oxo-1-propan-2-ylindol-3-ylidene)methyl]-3-phenylquinazolin-4-one

2-[(Z)-(2-oxo-1-propan-2-ylindol-3-ylidene)methyl]-3-phenylquinazolin-4-one

C26H21N3O2 (407.1634)


   

N-[2-[4-(3-chlorophenyl)-1-piperazinyl]ethyl]-[1,2,4]triazolo[4,3-a]quinoxalin-4-amine

N-[2-[4-(3-chlorophenyl)-1-piperazinyl]ethyl]-[1,2,4]triazolo[4,3-a]quinoxalin-4-amine

C21H22ClN7 (407.1625)


   

6,7-dimethoxy-2-[[methyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-1H-quinazolin-4-one

6,7-dimethoxy-2-[[methyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-1H-quinazolin-4-one

C21H21N5O4 (407.1593)


   
   
   
   
   
   
   

methyl 8-[(2E)-2-[[5-[(4,5-dimethyl-1,2,4-triazol-3-yl)sulfanyl]furan-2-yl]methylidene]hydrazinyl]-8-oxooctanoate

methyl 8-[(2E)-2-[[5-[(4,5-dimethyl-1,2,4-triazol-3-yl)sulfanyl]furan-2-yl]methylidene]hydrazinyl]-8-oxooctanoate

C18H25N5O4S (407.1627)


   
   
   
   

4-{[6-Endo-amino-6-exo-benzoyl-5-exo-phenylnorbornan-2-yl]oxy}-4-oxobutanoic acid

4-{[6-Endo-amino-6-exo-benzoyl-5-exo-phenylnorbornan-2-yl]oxy}-4-oxobutanoic acid

C24H25NO5 (407.1733)


   

acetylerucifoline N-oxide

acetylerucifoline N-oxide

C20H25NO8 (407.158)


A pyrrolizine alkaloid that is erucifoline in which the primary hydroxy hydrogen has been replaced by an acetyl group and the tertiary amino function has been oxidised to the corresponding N-oxide.

   

9-(1,3-Benzodioxol-5-yl)-6,7-dimethoxy-3,3-dimethyl-2,4,9,9a-tetrahydroacridin-1-one

9-(1,3-Benzodioxol-5-yl)-6,7-dimethoxy-3,3-dimethyl-2,4,9,9a-tetrahydroacridin-1-one

C24H25NO5 (407.1733)


   

N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-D-galactosaminyl group

N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-D-galactosaminyl group

C16H27N2O10 (407.1666)


An N-acetyl-D-galactosaminyl group obtained by removing the hydroxy group from the hemiacetal function of N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-D-galactosamine.

   

N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-alpha-D-galactosaminyl group

N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-alpha-D-galactosaminyl group

C16H27N2O10 (407.1666)


N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-D-galactosaminyl group with alpha-configuration at the reducing-end anomeric centre.

   
   

ST 18:4;O6;Gly

ST 18:4;O6;Gly

C20H25NO8 (407.158)


   

5-({1,4-bis[(4-hydroxyphenyl)methyl]imidazol-2-yl}amino)-2-hydroxy-3-methyl-5h-imidazol-4-one

5-({1,4-bis[(4-hydroxyphenyl)methyl]imidazol-2-yl}amino)-2-hydroxy-3-methyl-5h-imidazol-4-one

C21H21N5O4 (407.1593)


   

4-benzyl-9,9-dimethyl-6,15,17-trioxa-3-azapentacyclo[11.5.1.0¹,¹⁰.0²,⁷.0¹⁶,¹⁹]nonadeca-2,12-diene-5,18-dione

4-benzyl-9,9-dimethyl-6,15,17-trioxa-3-azapentacyclo[11.5.1.0¹,¹⁰.0²,⁷.0¹⁶,¹⁹]nonadeca-2,12-diene-5,18-dione

C24H25NO5 (407.1733)


   

5,10-dihydroxy-12-[(2r)-2-hydroxy-3-methylbut-3-en-1-yl]-2,2,11-trimethyl-1-oxa-11-azatetracen-6-one

5,10-dihydroxy-12-[(2r)-2-hydroxy-3-methylbut-3-en-1-yl]-2,2,11-trimethyl-1-oxa-11-azatetracen-6-one

C24H25NO5 (407.1733)


   

(1r,4s,7s,10s,19s)-4-benzyl-9,9-dimethyl-6,15,17-trioxa-3-azapentacyclo[11.5.1.0¹,¹⁰.0²,⁷.0¹⁶,¹⁹]nonadeca-2,12-diene-5,18-dione

(1r,4s,7s,10s,19s)-4-benzyl-9,9-dimethyl-6,15,17-trioxa-3-azapentacyclo[11.5.1.0¹,¹⁰.0²,⁷.0¹⁶,¹⁹]nonadeca-2,12-diene-5,18-dione

C24H25NO5 (407.1733)


   

5,10-dihydroxy-12-(2-hydroxy-3-methylbut-3-en-1-yl)-2,2,11-trimethyl-1-oxa-11-azatetracen-6-one

5,10-dihydroxy-12-(2-hydroxy-3-methylbut-3-en-1-yl)-2,2,11-trimethyl-1-oxa-11-azatetracen-6-one

C24H25NO5 (407.1733)